Institute of Fundamental Technological Research

The aim of the study was to improve monitoring the treatment response in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The IRB approved this prospective study. Ultrasound examinations were performed prior to treatment and 7 days after four consecutive NAC cycles. Residual malignant cell (RMC) measurement at surgery was the standard of reference. Alteration in B-mode ultrasound (tumor echogenicity and volume) and the Kullback-Leibler divergence (kld), as a quantitative measure of amplitude difference, were used. Correlations of these parameters with RMC were assessed and Receiver Operating Characteristic curve (ROC) analysis was performed. Thirty-nine patients (mean age 57 y.) with 50 tumors were included. There was a significant correlation between RMC and changes in quantitative parameters (KLD) after the second, third and fourth course of NAC, and alteration in echogenicity after the third and fourth course. Multivariate analysis of the echogenicity and KLD after the third NAC course revealed a sensitivity of 91%, specificity of 92%, PPV = 77%, NPV = 97%, accuracy = 91%, and AUC of 0.92 for non-responding tumors (RMC ≥ 70%). In conclusion, monitoring the echogenicity and KLD parameters made it possible to accurately predict the treatment response from the second course of NAC.

quantitative ultrasound, B-mode ultrasound, echogenicity, breast cancer, neoadjuvant chemotherapy

Objective: Neoadjuvant chemotherapy was initially used in locally advanced breast cancer, and currently it is recommended for patients with Stage 3 and with early-stage disease with human epidermal growth factor receptors positive or triple-negative breast cancer. Ultrasound imaging in combination with a quantitative ultrasound method is a novel diagnostic approach. Aim of study: The aim of this study was to analyze the variability of the integrated backscatter coefficient, and to evaluate their use to predict the effectiveness of treatment and compare to ultrasound examination results. Material and method: Ten patients (mean age 52.9) with 13 breast tumors (mean dimension 41 mm) were selected for neoadjuvant chemotherapy. Ultrasound was performed before the treatment and one week after each course of neoadjuvant chemotherapy. The dimensions were assessed adopting the RECIST criteria. Tissue responses were classified as pathological response into the following categories: not responded to the treatment (G1, cell reduction by ≤9%) and responded to the treatment partially: G2, G3, G4, cell reduction by 10–29% (G2), 30–90% (G3), >90% (G4), respectively, and completely. Results: In B-mode examination partial response was observed in 9/13 cases (completely, G1, G3, G4), and stable disease was demonstrated in 3/13 cases (completely, G1, G4). Complete response was found in 1/13 cases. As for backscatter coefficient, 10/13 tumors (completely, and G2, G3, and G4) were characterized by an increased mean value of 153%. Three tumors 3/13 (G1) displayed a decreased mean value of 31%. Conclusion: The variability of backscatter coefficient, could be associated with alterations in the structure of the tumor tissue during neoadjuvant chemotherapy. There were unequivocal differences between responded and non-responded patients. The backscatter coefficient analysis correlated better with the results of histopathological verification than with the B-mode RECIST criteria.

integrated backscatter coefficient (IBSCs), neoadjuvant chemotherapy (NAC), breast cancer, ultrasound

Background: Monitoring of response to neoadjuvant chemotherapy (NAC) in advanced breast cancer is crucial for assessing the effectiveness of the treatment and overall survival. The purpose of this study was to investigate the ability of classical ultrasound (US) examination and quantitative ultrasound (QU) parameters to predict the therapy response comparing to histology results after surgical treatment. Material and Methods: Two ultrasound backscatter parameters: the integrated backscatter coefficient, (IBSC) and shape parameter (M) of the homodyned K distribution, were estimated from ultrasonic radiofrequency (RF) signals. Sixteen patient with 22 breast cancer tumor treated with NAC sequential Anthracyclines and Taxanes were prospectively assessed. Data were acquired using 5–14 MHz array transducer, pre-chemotherapy, and four times during treatment (one week after the subsequent courses). The US results were compared with histological response analyzing the stromal changes and the cellularity of the tumor. Results: An increase in IBSC and decrease M parameters was observed in 80% of tumors with complete response after chemotherapy. It correlates with increasing the stromal elements, fibrosis, and elastosis. In patients with partial response, the parameters IBSC and M parameters did not change during subsequent cycles of treatment and allow predicting partial response in 70% of tumors. In pathological results, a similar cluster of cells without fibrosis and elastosis were observed. Conclusions: Ultrasound parameters derived from the RF data give the promise to predict the tumor response to NAC and better personalize the therapy using US QU examination. This study was supported by the National Science Centre, Poland, grant 2016/23/B/ST8/03391. No conflict of interest